Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis.

The drug maker behind miltefosine, the best treatment for amoeba infections, is taking a new approach to getting the drug on hospital shelves.

Miltefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphotericin B as the preferred treatments in some regions, but in other ...

The use of oral miltefosine, an antileishmanial agent, was evaluated in 5 patients (all contact lens users) diagnosed with progressive Acanthamoeba keratitis between January 2017 and January 2019.

Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal ...

Nov. 27, 2002 — Miltefosine is a safe and effective oral therapy for the treatment of visceral leishmaniasis, according to results of a randomized, open-label comparison published in the Nov. 28 ...

Until recently, miltefosine was only available from Germany. It is now one of several drugs used to treat rare diseases that the CDC keeps onsite in Atlanta.

Miltefosine, a broad-spectrum antimicrobial phospholipid drug originally developed as an anticancer agent, received FDA approval for the parasitic disease leishmaniasis in 2013, when the drug was ...

It's called Miltefosine, and it has been effective against similar microbes. Although this drug isn't approved for general use, the Centers for Disease Control and Prevention obtained special ...

Miltefosine was used to treat one of the survivors -- a 12-year-old girl in Arkansas, the CDC said. Miltefosine was originally developed to fight cancer in the 1980s.

To the Editor: The study by Sundar et al. (Nov. 28 issue)1 regarding oral miltefosine for the treatment of Indian visceral leishmaniasis is very promising. However, the reason for excluding from th ...